Turning Point Therapeutics Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics or view top-rated stocks.

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Turning Point Therapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 2,740,000 shares, a drop of 14.4% from the June 30th total of 3,200,000 shares. Based on an average daily trading volume, of 508,400 shares, the short-interest ratio is currently 5.4 days. Approximately 6.1% of the shares of the company are sold short.
View Turning Point Therapeutics' Short Interest.

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Turning Point Therapeutics.

Turning Point Therapeutics will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) issued its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.15. The business had revenue of $25.21 million for the quarter, compared to analyst estimates of $25 million.
View Turning Point Therapeutics' earnings history.

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TPTX stock has increased by 57.9% and is now trading at $64.02.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued twelve-month price targets for Turning Point Therapeutics' shares. Their forecasts range from $127.00 to $186.00. On average, they expect Turning Point Therapeutics' share price to reach $153.71 in the next year. This suggests a possible upside of 140.1% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Turning Point Therapeutics include Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), CureVac (CVAC), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Biohaven Pharmaceutical (BHVN), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR) and Evotec (EVTCY).
View all of TPTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Turning Point Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (2.93%), Handelsbanken Fonder AB (0.35%), Emerald Mutual Fund Advisers Trust (0.26%), Peregrine Capital Management LLC (0.25%), Emerald Advisers LLC (0.24%) and New York State Common Retirement Fund (0.11%). Company insiders that own Turning Point Therapeutics stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Siegfried Reich, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

TPTX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Cutler Group LP, Arizona State Retirement System, and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Turning Point Therapeutics company stock in the last year include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Mohammad Hirmand, Siegfried Reich, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics or view top insider-selling stocks.

TPTX stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Handelsbanken Fonder AB, Peregrine Capital Management LLC, Dupont Capital Management Corp, Oppenheimer & Co. Inc., New York State Common Retirement Fund, Advisors Asset Management Inc., and HighMark Wealth Management LLC. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Mark J Alles, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics or or view top insider-buying stocks.

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TPTX stock can currently be purchased for approximately $64.02.

Turning Point Therapeutics has a market capitalization of $3.15 billion and generates $25 million in revenue each year. The company earns $-157,290,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis.

Turning Point Therapeutics employs 142 workers across the globe.

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 926-5251 or via email at [email protected]